Financial Performance - Revenue for Q1 2024 was $16.6 million, up 30.5% from $12.7 million in Q1 2023, primarily due to collaboration with Pfizer and Sanofi[6] - Net loss for Q1 2024 was $41.5 million, or ($0.76) per share, compared to a net loss of $40.7 million, or ($0.75) per share, in Q1 2023[8] Expenses - Research and development expenses increased to $50.0 million in Q1 2024 from $45.8 million in Q1 2023, driven by clinical and manufacturing costs[7] - General and administrative expenses rose to $11.8 million in Q1 2024 compared to $9.8 million in Q1 2023, mainly due to higher stock-based compensation and professional service costs[8] Cash and Assets - Cash, cash equivalents, and marketable securities totaled $254.3 million as of February 29, 2024, down from $295.3 million as of November 30, 2023[9] - Total current assets decreased from $295,503 million in November 2023 to $250,969 million in February 2024, a decline of approximately 15%[18] - Cash and cash equivalents decreased from $54,627 million to $49,813 million, a reduction of about 9%[18] - Total assets decreased from $355,598 million to $312,674 million, a reduction of approximately 12%[18] Liabilities and Equity - Total liabilities decreased from $155,105 million in November 2023 to $143,926 million in February 2024, a decrease of approximately 7%[18] - Total stockholders' equity decreased from $200,493 million to $168,748 million, reflecting a decline of about 16%[18] - Accumulated deficit increased from $545,200 million to $586,718 million, indicating a worsening financial position[18] - Deferred revenue, net of current portion decreased from $45,022 million to $34,457 million, a decline of approximately 23%[18] - Additional paid-in-capital increased from $746,299 million to $755,767 million, showing a growth of about 1.9%[18] - Operating lease liabilities, net of current portion decreased from $23,125 million to $21,846 million, a reduction of approximately 5.5%[18] - Marketable securities, current decreased from $233,281 million to $194,180 million, a decline of about 17%[18] Collaborations and Research - Nurix extended its collaboration with Gilead Sciences, resulting in a $15 million extension fee and potential future milestones of up to $1.7 billion[3] - The collaboration with Sanofi for the STAT6 program was also extended, with a clinical candidate expected to be nominated within the next twelve months[3] - Nurix presented new clinical data for NX-5948, showing meaningful responses in patients with CNS lymphoma and CLL at the AACR 2024 Annual Meeting[3] - The company is part of a research team awarded in the Cancer Grand Challenges competition, focusing on developing targeted protein degraders for pediatric cancers[3] - Nurix plans to present additional clinical data for NX-5948 in mid-2024 and define doses for Phase 1b cohort expansion in CLL and NHL[10]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________________________________ __________________FORM _____________________________10-K ____________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________________________________________________ FORM 10-Q ______________________________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________________________________________________ FORM 10-Q ______________________________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ...

Table of Contents FORM 10-Q ______________________________________________________________________ (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________________________________________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fr ...

Table of Content UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________________________________ __________________FORM _____________________________10-K ____________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE T ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39398 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39398 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation ...

Nurix Therapeutics Blazing a New Path in Medicine Investor Presentation April 2022 Important Notice and Disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this presentation, the words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "outlook," "plan," "predict," "should," "will," and similar expre ...

Nurix Therapeutics Blazing a New Path in Medicine Investor Presentation April 2022 Important Notice and Disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this presentation, the words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "outlook," "plan," "predict," "should," "will," and similar expre ...